Tags

Type your tag names separated by a space and hit enter

Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
Ann Pharmacother. 2004 Dec; 38(12):2094-104.AP

Abstract

OBJECTIVE

To review the available literature addressing the role of low-molecular-weight heparin (LMWH) as an alternative to unfractionated heparin (UFH) in percutaneous coronary intervention (PCI) for treatment of non-ST-elevation acute coronary syndromes (NSTEACS).

DATA SOURCES

A MEDLINE search (1966-March 2004) identified pertinent articles using the key words acute coronary syndromes, unstable angina, non-ST-elevation myocardial infarction, low-molecular-weight heparin, enoxaparin, dalteparin, glycoprotein IIb/IIIa receptor antagonists, abciximab, tirofiban, eptifibatide, percutaneous transluminal coronary angioplasty, and percutaneous coronary intervention. The references of these articles were reviewed for additional pertinent references.

STUDY SELECTION AND DATA EXTRACTION

All human trials of LMWH in PCI for treatment of NSTEACS were evaluated. All pertinent studies were included in the review.

DATA SYNTHESIS

Administration of LMWH with or without a glycoprotein IIb/IIIa inhibitor during PCI appears to be similar to UFH in terms of efficacy. LMWH, especially in combination with a glycoprotein IIb/IIIa inhibitor, may increase risk of bleeding compared with UFH.

CONCLUSIONS

Available clinical trials do not provide definitive evidence to suggest superiority of LMWH over UFH when managing NSTEACS during PCI; however, dosing strategies are available if an LMWH is to be used in this setting.

Authors+Show Affiliations

Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201-2427, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15536140

Citation

Moser, Lynette R., and James S. Kalus. "Role of Low-molecular-weight Heparin in Invasive Management of non-ST-elevation Acute Coronary Syndromes." The Annals of Pharmacotherapy, vol. 38, no. 12, 2004, pp. 2094-104.
Moser LR, Kalus JS. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes. Ann Pharmacother. 2004;38(12):2094-104.
Moser, L. R., & Kalus, J. S. (2004). Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes. The Annals of Pharmacotherapy, 38(12), 2094-104.
Moser LR, Kalus JS. Role of Low-molecular-weight Heparin in Invasive Management of non-ST-elevation Acute Coronary Syndromes. Ann Pharmacother. 2004;38(12):2094-104. PubMed PMID: 15536140.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes. AU - Moser,Lynette R, AU - Kalus,James S, Y1 - 2004/11/09/ PY - 2004/11/13/pubmed PY - 2005/2/3/medline PY - 2004/11/13/entrez SP - 2094 EP - 104 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 38 IS - 12 N2 - OBJECTIVE: To review the available literature addressing the role of low-molecular-weight heparin (LMWH) as an alternative to unfractionated heparin (UFH) in percutaneous coronary intervention (PCI) for treatment of non-ST-elevation acute coronary syndromes (NSTEACS). DATA SOURCES: A MEDLINE search (1966-March 2004) identified pertinent articles using the key words acute coronary syndromes, unstable angina, non-ST-elevation myocardial infarction, low-molecular-weight heparin, enoxaparin, dalteparin, glycoprotein IIb/IIIa receptor antagonists, abciximab, tirofiban, eptifibatide, percutaneous transluminal coronary angioplasty, and percutaneous coronary intervention. The references of these articles were reviewed for additional pertinent references. STUDY SELECTION AND DATA EXTRACTION: All human trials of LMWH in PCI for treatment of NSTEACS were evaluated. All pertinent studies were included in the review. DATA SYNTHESIS: Administration of LMWH with or without a glycoprotein IIb/IIIa inhibitor during PCI appears to be similar to UFH in terms of efficacy. LMWH, especially in combination with a glycoprotein IIb/IIIa inhibitor, may increase risk of bleeding compared with UFH. CONCLUSIONS: Available clinical trials do not provide definitive evidence to suggest superiority of LMWH over UFH when managing NSTEACS during PCI; however, dosing strategies are available if an LMWH is to be used in this setting. SN - 1060-0280 UR - https://www.unboundmedicine.com/medline/citation/15536140/Role_of_low_molecular_weight_heparin_in_invasive_management_of_non_ST_elevation_acute_coronary_syndromes_ L2 - https://journals.sagepub.com/doi/10.1345/aph.1E176?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -